Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare read-only, idempotent, non-destructive behavior, so the bar is lower. The description adds a free-beta caveat and lists returned fields, but does not disclose formatting, pagination, limits, or provenance meaning.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

Eleven words with no filler; the free-beta caveat is front-loaded and the return contents are stated efficiently. The description is appropriately sized for its scope.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a 3-parameter tool with no output schema and a close basic sibling, this is thin. It names result fields but not their shape, gives no pagination or date-format expectations, and offers no rationale for choosing evidence over basic.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 0%, and the description does not explain query, category, or limit semantics. Category's enum is self-explanatory and query/limit are guessable, but the description adds no parameter-level value to compensate for the schema gap.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific resource (FDA recalls) and what it returns (matches with reason, dates, distribution, provenance), so an agent knows the tool searches recall records. It does not explicitly contrast with the sibling fda_recall_search_basic, so it misses the top score for sibling differentiation.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

No guidance on when to use the evidence variant instead of fda_recall_search_basic or other evidence tools. 'FREE beta' signals status, not selection criteria, leaving the agent to infer usage from the suffix.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.